Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal ( <scp>CANVAS‐R</scp> ): A randomized, placebo‐controlled trial

Abstract

The trial should define the potential renoprotective effect of canagliflozin and will provide additional important new data about its effects on vascular outcomes, death and kidney failure.